<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Solvonis Therapeutics Plc — News on 6ix</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc</link>
<description>Latest news and press releases for Solvonis Therapeutics Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/solvonis-therapeutics-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d58936beedb30cb6f8cdc9.webp</url>
<title>Solvonis Therapeutics Plc</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc</link>
</image>
<item>
<title>Appointment of Water Tower Research</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/appointment-of-water-tower-research</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/appointment-of-water-tower-research</guid>
<pubDate>Wed, 22 Apr 2026 06:00:00 GMT</pubDate>
<description>Solvonis Therapeutics plc has appointed Water Tower Research LLC to enhance its understanding of the U.S. market, refine its corporate profile, and expand institutional investor reach, particularly as it advances its pipeline programs including SVN-002 for alcohol use disorder, SVN-015 for stimulant addiction, and SVN-114 for PTSD. This strategic move aims to address a perceived valuation gap with comparable U.S.-listed CNS peers and strengthen the company's equity story within the crucial U.S. </description>
</item>
<item>
<title>US CNS Executive Order</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/us-cns-executive-order</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/us-cns-executive-order</guid>
<pubDate>Mon, 20 Apr 2026 07:32:00 GMT</pubDate>
<description>Solvonis Therapeutics plc welcomes President Trump's Executive Order on accelerating medical treatments for serious mental illness, viewing it as a positive signal for rapid-acting CNS and psychedelic-adjacent therapies, particularly in the U.S. market. While not directly related to specific company programs, the order is highly relevant to Solvonis' pipeline, which includes SVN-001 for severe alcohol use disorder, SVN-002 for moderate-to-severe alcohol use disorder in the U.S., SVN-015 for stim</description>
</item>
<item>
<title>Granted U.S. Patent from PTSD Discovery Programme</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/granted-us-patent-from-ptsd-discovery-programme</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/granted-us-patent-from-ptsd-discovery-programme</guid>
<pubDate>Wed, 08 Apr 2026 06:00:00 GMT</pubDate>
<description>Solvonis Therapeutics plc has been granted a second U.S. patent, U.S. Patent No. 12,595,269, covering a new series of monoamine modulator compounds from its post-traumatic stress disorder (PTSD) discovery program, with patent protection expected until February 2043. This composition-of-matter patent, which protects the compounds themselves, reinforces the breadth of the company's research platform and strengthens its intellectual property estate in the PTSD therapeutic area, complementing recent</description>
</item>
<item>
<title>SVN-114 selected for PTSD discovery programme</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/svn-114-selected-for-ptsd-discovery-programme</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/svn-114-selected-for-ptsd-discovery-programme</guid>
<pubDate>Tue, 10 Mar 2026 07:00:00 GMT</pubDate>
<description>Solvonis Therapeutics plc has announced the selection of SVN-114 as the lead candidate from its SVN-SDN-14 discovery program targeting Post-Traumatic Stress Disorder (PTSD), a condition affecting over 20 million people globally with limited pharmacological treatments. Preclinical studies conducted by Evotec SE demonstrated that SVN-114 exhibits balanced modulation of serotonin, dopamine, and noradrenaline transporters, key neurotransmitters involved in mood and social behavior. This selection, a</description>
</item>
<item>
<title>Expansion of SVN-015 into depression</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/expansion-of-svn-015-into-depression</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/expansion-of-svn-015-into-depression</guid>
<pubDate>Wed, 28 Jan 2026 07:00:00 GMT</pubDate>
<description>Solvonis Therapeutics plc announced the expansion of its investigational compound SVN-015 into depression treatment, following preclinical data demonstrating antidepressant-like activity comparable to fluoxetine after 14-day, once-daily dosing in rodent models. SVN-015 is a novel Serotonin-Dopamine Reuptake Inhibitor designed to target pathways involved in mood, motivation, and reward processing, potentially benefiting patients with inadequate SSRI response, particularly those experiencing anhed</description>
</item>
<item>
<title>US Patent allowance for PTSD discovery programme</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/us-patent-allowance-for-ptsd-discovery-programme</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/us-patent-allowance-for-ptsd-discovery-programme</guid>
<pubDate>Wed, 07 Jan 2026 07:00:00 GMT</pubDate>
<description>Solvonis Therapeutics plc has received a Notice of Allowance from the United States Patent and Trademark Office for compounds within its SVN-SDN-14 Post-Traumatic Stress Disorder discovery programme, strengthening its intellectual property as a lead compound is expected in Q1 2026. This patent covers a novel chemical series designed to modulate serotonin, dopamine, and noradrenaline pathways with improved pharmacological control, addressing historical challenges in developing effective PTSD ther</description>
</item>
<item>
<title>Research and Development Update – Q4 2025</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/research-and-development-update-q4-2025</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/research-and-development-update-q4-2025</guid>
<pubDate>Mon, 22 Dec 2025 07:00:00 GMT</pubDate>
<description>Solvonis Therapeutics plc provided a Q4 2025 research and development update, highlighting progress in addiction and psychiatry with multiple anticipated catalysts in 2026. The lead program, SVN-001 for severe alcohol use disorder, is in a Phase 3 trial with top-line results expected late 2027 or early 2028. SVN-002, an oral esketamine thin-film for moderate-to-severe AUD, is progressing with pharmacokinetic bridging expected in Q1 2026, aiming for a US FDA Phase 2b trial. SVN-015, a novel compo</description>
</item>
<item>
<title>SVN-015 accepted into US NIDA funded programme</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/svn-015-accepted-into-us-nida-funded-programme</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/svn-015-accepted-into-us-nida-funded-programme</guid>
<pubDate>Wed, 03 Dec 2025 07:00:00 GMT</pubDate>
<description>Solvonis Therapeutics plc announced that its novel compound SVN-015 has been accepted into the US National Institute on Drug Abuse's Addiction Treatment Discovery Program for methamphetamine and cocaine addiction, with NIDA funding early preclinical safety and efficacy studies. Successful completion could lead to non-dilutive NIH research grants of up to $3 million annually for five years, potentially funding human clinical trials. This marks an expansion of Solvonis' research into stimulant add</description>
</item>
<item>
<title>Total Voting Rights</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/total-voting-rights-983</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/total-voting-rights-983</guid>
<pubDate>Fri, 31 Oct 2025 15:59:00 GMT</pubDate>
<description>Solvonis Therapeutics plc announced that its issued share capital as of October 31, 2025, comprises 6,806,403,493 ordinary shares, each with one voting right. The company holds no ordinary shares in treasury, resulting in a total of 6,806,403,493 ordinary shares and voting rights. This includes a correction to a previously announced share issue on the same date, with the accurate figure for shares issued and admitted being 23,636,362, revised down from the originally stated 26,636,362 shares. Th</description>
</item>
<item>
<title>Appoints global biopharma leader Paul Carter</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/appoints-global-biopharma-leader-paul-carter</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/appoints-global-biopharma-leader-paul-carter</guid>
<pubDate>Mon, 27 Oct 2025 07:00:00 GMT</pubDate>
<description>Solvonis Therapeutics plc announced the appointment of Paul Carter as a Non-Executive Director, effective October 27, 2025. In connection with the appointment, Mr. Carter was granted 21 million share options under the company's long-term incentive plan. These options are exercisable at a price of £0.0034 per share, representing ordinary shares of £0.001 each. The options vest in three equal tranches, with one-third vesting on the grant date, another third on the first anniversary, and the final </description>
</item>
<item>
<title>Raises £1.25 Million to Accelerate Programmes</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/raises-pound125-million-to-accelerate-programmes</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/raises-pound125-million-to-accelerate-programmes</guid>
<pubDate>Thu, 16 Oct 2025 06:00:00 GMT</pubDate>
<description>Solvonis Therapeutics PLC successfully raised £1.25 million (gross) through a direct subscription with institutional and strategic investors. The subscription was priced at £0.0033 per new ordinary share, representing an approximate 13% discount to the closing mid-market price on October 15, 2025. This will result in the issue of 378,787,876 new ordinary shares of £0.001 each. The company intends to use the proceeds to broaden its research and development activities across addiction, psychiatry,</description>
</item>
<item>
<title>Half-year Report</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/half-year-report-805</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/half-year-report-805</guid>
<pubDate>Tue, 30 Sep 2025 06:00:00 GMT</pubDate>
<description>Solvonis Therapeutics PLC announced its unaudited interim results for the six months ending June 30, 2025. The company's cash and cash equivalents at the period's end totaled £1,719,000, a significant increase from £27,000 in H1 2024. The loss before taxation for the period was £1,621,000, compared to £469,000 in the previous year. The Group's net assets at the period-end were £6,935,000, up from £3,084,000 at the end of 2024, while total assets reached £9,545,000, increasing from £3,203,000 at </description>
</item>
<item>
<title>Solvonis secures exclusive CNS collaboration</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/solvonis-secures-exclusive-cns-collaboration</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/solvonis-secures-exclusive-cns-collaboration</guid>
<pubDate>Thu, 28 Aug 2025 06:00:00 GMT</pubDate>
<description>Solvonis Therapeutics announced amendments to its consultancy agreement with CSO Professor David Nutt, who will now work exclusively with the company on CNS drug discovery and development and serve as Interim Chair of a newly established Scientific Advisory Committee. Additionally, Solvonis has agreed to settle £286,681 in outstanding liabilities by issuing 141,875,231 new ordinary shares. This includes 81,732,308 shares at £0.0013 each and 60,142,923 shares at £0.003 each. Application has been </description>
</item>
<item>
<title>Media Coverage: Small Cap Idea profile</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/media-coverage-small-cap-idea-profile</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/media-coverage-small-cap-idea-profile</guid>
<pubDate>Wed, 13 Aug 2025 14:03:00 GMT</pubDate>
<description>Media Coverage: Small Cap Idea profile.</description>
</item>
<item>
<title>SVN-SDN-14 PTSD - Positive pre-clinical results</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/svn-sdn-14-ptsd-positive-pre-clinical-results</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/svn-sdn-14-ptsd-positive-pre-clinical-results</guid>
<pubDate>Tue, 12 Aug 2025 06:00:00 GMT</pubDate>
<description>SVN-SDN-14 PTSD - Positive pre-clinical results.</description>
</item>
<item>
<title>Translational Bridging Studies</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/translational-bridging-studies</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/translational-bridging-studies</guid>
<pubDate>Tue, 22 Jul 2025 06:00:00 GMT</pubDate>
<description>Translational Bridging Studies.</description>
</item>
<item>
<title>Exercise of warrants</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/exercise-of-warrants-107</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/exercise-of-warrants-107</guid>
<pubDate>Fri, 18 Jul 2025 10:03:00 GMT</pubDate>
<description>Exercise of warrants.</description>
</item>
<item>
<title>Solvonis Chair to speak at Lucid Capital Markets</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/solvonis-chair-to-speak-at-lucid-capital-markets</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/solvonis-chair-to-speak-at-lucid-capital-markets</guid>
<pubDate>Mon, 14 Jul 2025 06:00:00 GMT</pubDate>
<description>Solvonis Chair to speak at Lucid Capital Markets.</description>
</item>
<item>
<title>£1m subscription to accelerate AI drug discovery</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/pound1m-subscription-to-accelerate-ai-drug-discovery</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/pound1m-subscription-to-accelerate-ai-drug-discovery</guid>
<pubDate>Fri, 11 Jul 2025 06:00:00 GMT</pubDate>
<description>£1m subscription to accelerate AI drug discovery.</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/solvonis-therapeutics-plc/news/holdings-in-company-1341</link>
<guid isPermaLink="true">https://6ix.com/company/solvonis-therapeutics-plc/news/holdings-in-company-1341</guid>
<pubDate>Tue, 08 Jul 2025 06:00:00 GMT</pubDate>
<description>Holding(s) in Company.</description>
</item>
</channel>
</rss>